AzTrials
AzTrials

Advanced Solid Tumors With Bone Only MetastasisPhase 2NCT06416358

A Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed

A Phase 2 study testing ALMB-0168 in people with Advanced Solid Tumors With Bone Only Metastasis, run by AlaMab Therapeutics (Shanghai) Inc..

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Bone metastasis is a common disease of advanced tumors. It refers to the metastasis of malignant tumors originating in a certain organ to the bones through the blood circulation or lymphatic system. The incidence of bone metastasis in breast and prostate cancer is as high as 65%-75%. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
ALMB-0168
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
144 participants
Where
No sites listed yet
Study dates
May 2024to Dec 2026
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Histologically or cytologically pathologically confirmed solid tumors.
  • presence of any of the following:
  • Cohort A breast cancer with bone metastases: patients with disease progression or intolerance to prior standard therapy (e.g., radiotherapy, chemotherapy, endocrine therapy, anti-Her2 targeted therapy) and the presence of bone metastatic lesions only.
  • Among them, Cohort A needs to fulfill the following points:
  • For hormone receptor-positive breast cancer: endocrine therapy (including, but not limited to, ET with or without combination of CDK 4/6 inhibitors, the mTOR inhibitor everolimus, the HDAC inhibitor cedarbenamide, and the PI3Kα inhibitor Alpelisib, among others) is required and progression or intolerance; ii. For Her2-positive (defined as FISH/CISH/SISH positive or IHC 3+ or IHC 2+ but confirmed HER2-positive by in situ hybridization) breast cancers: anti-Her2 targeted therapies (including trastuzumab/patuzumab or marketed biosimilars or initumumab or anti-Her2 ADCs such as T-DM1/DS8201 or TKIs) are required. DS8201 or TKI analogs (lapatinib, pyrrolitinib, neratinib, tucatinib, etc.)) and progression or intolerance; iii. For BRCA1/2 germline mutant breast cancer: progression or intolerance to olaparib is required; iv. PD-L1-positive with combined positive (CPS) score ≥10 requiring anti-PD-1, PD-L1 progression or intolerance; v. Disease progression or intolerance from at least 1 chemotherapy regimen, or unsuitable for chemotherapy; b. Cohort B prostate cancer with bone metastases: metastatic desmoplasia-resistant prostate cancer that meets PCWG3 progression criteria after prior standard therapy (e.g., docetaxel or abiraterone, enzalutamide, etc.), and the presence of bone metastatic lesions (≥2) only.
  • Of these, Cohort B needs to fulfill the following points:
Show all 13Show fewer
  • Receiving or maintaining androgen deprivation therapy (ADT) during the study period (i.e., ongoing treatment with gonadotropin-releasing hormone (GnRH) agonists or antagonists (pharmacologic depot) or previous bilateral orchiectomy (surgical depot)), and serum testosterone must be at depot levels (< 50 ng/mL or < 1.7 nmol/L); ii. Must have progressed or been intolerant to at least 1 novel endocrine therapy (including enzalutamide/abiraterone/apatadine/darotarolimide, etc.) during the mCRPC phase; iii. Have received 1 paclitaxel-based chemotherapy regimen disease progression or intolerance, or are not suitable to receive paclitaxel.
  • 18 years old and above, male and female.
  • ECOG (Eastern Cooperative Oncology Group) PS score of 0, 1, or 2.
  • Major systemic functions are defined as follows:
  • Bone marrow reserve: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L; platelet count ≥ 75 x 109/L; hemoglobin ≥ 90 g/L, and no related supportive therapy such as GCS-F, EPO, or transfusion had been used in the 14 days prior to dosing; ii. Liver function: Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) (unless the patient has grade 1 bilirubin elevation due to Gilbert's disease or a similar syndrome of slow bilirubin binding). Transaminases (AST/SGOT and/or ALT/SGPT) ≤ 3 times ULN; iii.Renal function: Normal serum creatinine ≤ 1.5 mg/dL (133 μmol / L) and calculated creatinine clearance ≥ 60 mL/min (Cockroft - Gault formula); iv. Coagulation: Coagulation parameters defined as an international normalized rate (INR) ≤ 2.
  • 6 Eligible individuals of childbearing potential (males and females) must agree to use a reliable method of contraception (hormonal contraceptives, barrier method, or abstinence) with their partner for the duration of the trial and for at least 60 days after the last dose. Female individuals of childbearing age must have a negative blood pregnancy test within 7 days prior to enrollment and must be non-lactating. Male subjects are prohibited from donating sperm during their participation in the study and female subjects are prohibited from donating eggs during the study.
  • 7. Expected survival of ≥ 3 months. 8. Be able to understand the whole process of the study, participate voluntarily and sign the informed consent form.

Who cannot join

  • Clinically uncontrolled pleural effusion, abdominal effusion, pericardial effusion (except for small amounts detected by imaging) within 4 weeks prior to dosing.
  • Poorly controlled bone pain, pathologic long bone fracture (> 50% cortical erosion on imaging), or neoplastic spinal cord compression.
  • Systemic glucocorticoid therapy within 4 weeks prior to dosing (except >20 mg/day of prednisone or equivalent dose of other hormones for prevention of contrast reactions during radiologic exams or inhalation or topical administration).
  • Following cardiac conditions within 6 months prior to dosing:
  • Left ventricular ejection fraction (LVEF) < 45% as measured by echocardiography (ECHO);
  • Screening electrocardiogram (ECG) suggesting a QTcF interval > 470 ms in women and > 450 ms in men;
Show all 20Show fewer
  • Unstable angina;
  • Congestive heart failure (New York Heart Association [NYHA] > class 2);
  • Acute myocardial infarction;
  • Poorly controlled arrhythmias;
  • Stent implantation.
  • Uncontrolled hypertension. (Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg.
  • Severe active bacterial, fungal, or viral infection (defined as requiring intravenous antibacterial, antifungal, or antiviral drug therapy) within 2 weeks prior to the first dose, or other serious medical condition that would interfere with the subject's ability to receive the test drug.
  • Positive anti-human immunodeficiency virus antibody or anti-syphilis spirochete-specific antibody tests, or active hepatitis B (defined as hepatitis B surface antigen positive and HBV-DNA above the lower measurable limit or ≥ 500 IU/ml) or active hepatitis C (defined as HCV antibody positive and HCV-RNA positive).
  • Other active tumors or a history of treatment for invasive tumors within 3 years. Subjects with a history of definitive local therapy for stage I tumors that are considered unlikely to recur are acceptable. Patients with a history of prior treatment for carcinoma in situ (e.g., non-invasive) and a history of non-melanoma skin cancer may be accepted.
  • Recent antineoplastic therapy (including but not limited to chemotherapy, immunotherapy, endocrine therapy and targeted therapy, but also including unlisted antineoplastic therapy) ≤ 4 weeks or within 5 half-lives of the drug, whichever is shorter, prior to the first dose, or relevant side effects NCI CTCAE v5.0 > Grade 1, except alopecia.
  • Participation in a clinical trial of another drug within 4 weeks prior to the first dose or within 5 half-lives of the trial drug, whichever is shorter, and enrollment in treatment, unless it is an observational (non-interventional) clinical trial or in the follow-up period of an interventional trial.
  • Radiation therapy (including radioisotope therapy such as strontium 89) ≤ 4 weeks prior to the first dose or localized radiation therapy ≤ 1 week prior to treatment, or have not recovered from the side effects of such therapy.
  • Surgery within 4 weeks prior to the first dose or outpatient surgery within 1 week prior to the start of treatment. There is no waiting period after artificial blood vessel placement.
  • 13．Herbal or proprietary Chinese medicine with antitumor activity within 1 week prior to the first dose; 14. Previous grade ≥ 3 hypersensitivity and/or contraindications to human monoclonal antibodies or fusion proteins; 15. Pregnant or lactating women. 16. Individuals who, in the opinion of the investigator, are otherwise unsuitable for participation in this clinical trial.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

Clinical Trials Information Group officer contact

86-0311-69085587

ctr-contact@cspc.cn

About this study

Official title: A Phase IIa, Multi-center, Single-Arm, Open-Label Study to Evaluate the Efficacy of ALMB-0168 in Solid Tumor Patients With Bone Metastatic Whose Prior Standard Treatment Have Failed

Bone metastasis is a common disease of advanced tumors. It refers to the metastasis of malignant tumors originating in a certain organ to the bones through the blood circulation or lymphatic system. The incidence of bone metastasis in breast and prostate cancer is as high as 65%-75%. Bone metastasis of malignant tumors often leads to severe bone lesions, including bone pain, pathological fractures, spinal cord compression, hypercalcemia and other bone-related events (SRE). SRE caused by bone metastasis of tumors can greatly reduce the quality of life of tumor patients. In severe cases, it can lead to rapid deterioration of the condition or even death, which greatly affects the extension of the patient's survival period. ALMB-0168 is designed to activate Cx43 hemichannels, which release key anti-cancer factors (such as ATP) into the extracellular environment. In several mouse models of breast cancer bone metastasis and orthotopic osteosarcoma, ALMB-0168 dose-dependently inhibited tumor growth and was able to extend the lifespan of tumor-bearing animals, indicating its potential as a therapeutic drug for malignant bone tumors. . Clinical research data from China and Australia show that ALMB-0168 is safe and initially effective in patients with bone metastasis and osteosarcoma;

Read the detailed description

Avoid duplicating information that will be entered elsewhere, such as Eligibility Criteria or Outcome Measures.

Being tested
ALMB-0168

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ALMB-0168Drug

    ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.

Study groups in NCT06416358
Study groupRoleWhat they receive
ALMB-0168ExperimentalNot described
Receives: Drug: ALMB-0168

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The 6-month progression-free survival rate (6m-PFSR) of cohort A breast cancer IRC assessed according to RECIST 1.1 criteria

    time (in months) from enrollment to occurrence of any one of following: radiological tumor progressions using response evaluation criteria in solid tumors (RECIST 1.1), progression of bone lesions using Prostate Cancer Working Group 3 (PCWG2) criteria or occurrence of death due to any cause. Progression as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Progression of bone lesions (PCWG3 criteria): first bone scan with >= 2 new lesions compared to Baseline observed less than (<) 12 weeks from enrollment and confirmed by a second bone scan performed >=6 weeks; first bone scan with >=2 new lesions compared to Baseline observed >=12 weeks from enrollment

    Measured: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to approximately 3 years

  2. The 4-month progression-free survival rate (6m-PFSR) assessed by cohort B prostate cancer Independent Review Committee（IRC） based on PCWG 3 criteria Progression-free survival rate (4m-PFSR);

    Measured: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to approximately 3 years

  3. RP2D

    To determine the recommended Phase 2 dose (RP2D) of single agent ALMB-0168 (monotherapy) for further exploration

    Measured: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to approximately 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 May 2024
  2. Study startMay 2024 (estimated)
  3. Primary completionJun 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
144 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06416358
Sponsor's protocol ID
ALMB-0168-002
Status last verified
May 2024
First submitted
10 May 2024
Last updated
16 May 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing ALMB-0168 in people with Advanced Solid Tumors With Bone Only Metastasis, run by AlaMab Therapeutics (Shanghai) Inc..

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 16 May 2024. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Clinical Trials Information Group officer (86-0311-69085587, ctr-contact@cspc.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The 6-month progression-free survival rate (6m-PFSR) of cohort A breast cancer IRC assessed according to RECIST 1.1 criteria (time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, up to approximately 3 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06416358.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 May 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in